From Surf Wiki (app.surf) — the open knowledge base

BMS-345541

Chemical compound

| elimination_half-life =

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.

References

The Journal of Biological Chemistry. 2003. 278. 1450-1456.
[https://clinicaltrials.gov/ct2/results?term=BMS-345541&Search=Search no studies found for: BMS-345541]

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

anti-inflammatory-agents drugs-developed-by-merck heterocyclic-compounds-with-3-rings

Want to explore this topic further?

Ask Mako anything about BMS-345541 — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report